Pharmaceutical advertising

Indication: Pulmonary Arterial Hypertension

HCP Marketing | Product Launch | Ongoing Brand Support

The Challenge
WINREVAIR launched in 2023 as the first and only activin signaling inhibitor (ASI) for PAH. Two subsequent study readouts expanded the patient population and added to an already robust data set that many HCPs found difficult to navigate.

The Approach
As lead copywriter since launch, I focused on evolving the HCP narrative without adding complexity. The strategy centered on streamlining new clinical data into a clear hierarchy while maintaining consistency with the original launch story, all within a highly rigorous regulatory environment.

My Role
Led copy development for updated core HCP materials supporting two new studies, ensuring clarity, compliance, and continuity across the brand’s lifecycle.

Outcome
Updated materials helped simplify an expanding body of evidence, enabling clearer field conversations as WINREVAIR continued to evolve post-launch.